Premium
Decreasing New York esophageal squamous cell carcinoma 1 expression inhibits multiple myeloma growth and osteolytic lesions
Author(s) -
Li Fei,
Zhao Fengshu,
Li Miao,
Pan Meng,
Shi Fangfang,
Xu Hui,
Zheng Danfeng,
Wang Ling,
Dou Jun
Publication year - 2020
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.29128
Subject(s) - gene knockdown , cell growth , cancer research , small hairpin rna , cadherin , cell , cell migration , epithelial–mesenchymal transition , cell cycle , chemistry , biology , medicine , cell culture , cancer , metastasis , biochemistry , genetics
New York esophageal squamous cell carcinoma 1 (NY‐ESO‐1) is aberrantly expressed in multiple myeloma (MM) patients, however, its role remains largely unknown. The present study aimed to investigate the effect of NY‐ESO‐1 knockdown on MM impact and provide evidence for targeting treatment of MM. Human MM U266 cells were infected with lentivirus‐based small hairpin RNA‐targeting NY‐ESO‐1 (LV‐shNY‐ESO‐1). Cellular proliferation, colony‐forming, migration, and invasion assays were employed. The expressions of cell cycle and epithelial–mesenchymal transition (EMT)‐related molecules, MM growth, and mouse osteolytic lesions were evaluated. The results showed that the LV‐shNY‐ESO‐1‐U266 cells had a lower expression of NY‐ESO‐1 and a higher expressions of p21 and E‐cadherin, and a weaker abilities of colony formation, drug‐resistant to adriamycin, migration, and invasion than those of the control cells. Importantly, the knockdown of NY‐ESO‐1 inhibited significantly the U266 cell‐induced MM growth and osteolytic lesions along with increasing the expressions of E‐cadherin, p21, and p53 in mice challenged with LV‐shNY‐ESO‐1‐U266 cells. Collectively, our findings demonstrate that knockdown of NY‐ESO‐1 suppressed the U266 cell‐induced MM growth and osteolytic lesions by inhibition of the MMs cell cycle and EMT. The NY‐ESO‐1 knockdown may be considered for future clinical trials in MM.